Opposite prognostic roles of HIF1α and HIF2α expressions in bone metastatic clear cell renal cell cancer

DSpace/Manakin Repository

Opposite prognostic roles of HIF1α and HIF2α expressions in bone metastatic clear cell renal cell cancer

Citable link to this page

 

 
Title: Opposite prognostic roles of HIF1α and HIF2α expressions in bone metastatic clear cell renal cell cancer
Author: Szendrői, Attila; Szász, A. Marcell; Kardos, Magdolna; Tőkés, Anna-Mária; Idan, Roni; Szűcs, Miklós; Kulka, Janina; Nyirády, Péter; Szendrői, Miklós; Szállási, Zoltán; Győrffy, Balázs; Tímár, József

Note: Order does not necessarily reflect citation order of authors.

Citation: Szendrői, A., A. M. Szász, M. Kardos, A. Tőkés, R. Idan, M. Szűcs, J. Kulka, et al. 2016. “Opposite prognostic roles of HIF1α and HIF2α expressions in bone metastatic clear cell renal cell cancer.” Oncotarget 7 (27): 42086-42098. doi:10.18632/oncotarget.9669. http://dx.doi.org/10.18632/oncotarget.9669.
Full Text & Related Files:
Abstract: BACKGROUND Prognostic markers of bone metastatic clear cell renal cell cancer (ccRCC) are poorly established. We tested prognostic value of HIF1α/HIF2α and their selected target genes in primary tumors and corresponding bone metastases. RESULTS Expression of HIF2α was lower in mRCC both at mRNA and protein levels (p/mRNA/=0.011, p/protein/=0.001) while HIF1α was similar to nmRCC. At the protein level, CAIX, GAPDH and GLUT1 were increased in mRCC. In all primary RCCs, low HIF2α and high HIF1α as well as CAIX, GAPDH and GLUT1 expressions correlated with adverse prognosis, while VEGFR2 and EPOR gene expressions were associated with favorable prognosis. Multivariate analysis confirmed high HIF2α protein expression as an independent risk factor. Prognostic validation of HIFs, LDH, EPOR and VEGFR2 in RNA-Seq data confirmed higher HIF1α gene expression in primary RCC as an adverse (p=0.07), whereas higher HIF2α and VEGFR2 expressions as favorable prognostic factors. HIF1α/HIF2α-index (HIF-index) proved to be an independent prognostic factor in both the discovery and the TCGA cohort. PATIENTS AND METHODS Expressions of HIF1α and HIF2α as well as their 7 target genes were analysed on the mRNA and protein level in 59 non-metastatic ccRCCs (nmRCC), 40 bone metastatic primary ccRCCs (mRCC) and 55 corresponding bone metastases. Results were validated in 399 ccRCCs from the TCGA project. CONCLUSIONS We identified HIF2α protein as an independent marker of the metastatic potential of ccRCC, however, unlike HIF1α, increased HIF2α expression is a favorable prognostic factor. The HIF-index incorporated these two markers into a strong prognostic biomarker of ccRCC.
Published Version: doi:10.18632/oncotarget.9669
Other Sources: http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5173118/pdf/
Terms of Use: This article is made available under the terms and conditions applicable to Other Posted Material, as set forth at http://nrs.harvard.edu/urn-3:HUL.InstRepos:dash.current.terms-of-use#LAA
Citable link to this page: http://nrs.harvard.edu/urn-3:HUL.InstRepos:29738971
Downloads of this work:

Show full Dublin Core record

This item appears in the following Collection(s)

 
 

Search DASH


Advanced Search
 
 

Submitters